Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06643910
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-14
Brief Title:
A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an exploratory clinical trial initiated by an open single arm researcher to evaluate the safety tolerability and preliminary efficacy of BST08 in the treatment of advanced non-small cell lung cancer in subjects This study plans to set up two experimental groups monotherapy group A 9x10 10 BST08 3 cases and combination therapy group B 9x10 10 BST08Pabolizhu 200mg Q3W 6 cases
Detailed Description:
Main purpose
Evaluate the safety and tolerability of BST08 treatment in subjects with advanced non-small cell lung cancer
Secondary purpose
1 Evaluate the preliminary effectiveness of BST08 in the treatment of advanced non-small cell lung cancer subjects
2 Evaluate the pharmacokinetic PK characteristics of BST08
Evaluate the safety and tolerability of BST08 treatment in subjects with advanced non-small cell lung cancer
Secondary purpose
1 Evaluate the preliminary effectiveness of BST08 in the treatment of advanced non-small cell lung cancer subjects
2 Evaluate the pharmacokinetic PK characteristics of BST08
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None